Search

Your search keyword '"Riisnaes, Ruth"' showing total 6 results
Start Over Author "Riisnaes, Ruth" Journal journal of clinical investigation
6 results on '"Riisnaes, Ruth"'

1. RNASEH2B loss and PARP inhibition in advanced prostate cancer

Author

Carmichael, Juliet, primary, Figueiredo, Ines, additional, Gurel, Bora, additional, Beije, Nick, additional, Yuan, Wei, additional, Rekowski, Jan, additional, Seed, George, additional, Carreira, Suzanne, additional, Bertan, Claudia, additional, Fenor de la Maza, Maria de Los Dolores, additional, Chandran, Khobe, additional, Neeb, Antje, additional, Welti, Jon, additional, Gallagher, Lewis, additional, Bogdan, Denisa, additional, Crespo, Mateus, additional, Riisnaes, Ruth, additional, Ferreira, Ana, additional, Miranda, Susana, additional, Lu, Jinqiu, additional, Shen, Michael M., additional, Hall, Emma, additional, Porta, Nuria, additional, Westaby, Daniel, additional, Guo, Christina, additional, Grochot, Rafael, additional, Lord, Christopher J., additional, Mateo, Joaquin, additional, Sharp, Adam, additional, and de Bono, Johann, additional

Published
2024
Full Text
View/download PDF

2. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer

Author

Sharp, Adam, Coleman, Ilsa, Yuan, Wei, Sprenger, Cynthia, Dolling, David, Rodrigues, Daniel Nava, Russo, Joshua W., Figueiredo, Ines, Bertan, Claudia, Seed, George, Riisnaes, Ruth, Uo, Takuma, Neeb, Antje, Welti, Jonathan, Morrissey, Colm, Carreira, Suzanne, Luo, Jun, Nelson, Peter S., Balk, Steven P., True, Lawrence D., de Bono, Johann S., and Plymate, Stephen R.

Subjects
Biology -- Usage, Cancer patients -- Health aspects, Gene expression -- Research, Prostate cancer -- Genetic aspects -- Diagnosis -- Development and progression, Health care industry
Abstract

BACKGROUND. Liquid biopsies have demonstrated that the constitutively active androgen receptor splice variant-7 (AR-V7) associates with reduced response and overall survival from endocrine therapies in castration-resistant prostate cancer (CRPC). However, these studies provide little information pertaining to AR-V7 expression in prostate cancer (PC) tissue.METHODS. Following generation and validation of a potentially novel AR-V7 antibody for IHC, AR-V7 protein expression was determined for 358 primary prostate samples and 293 metastatic biopsies. Associations with disease progression, full-length androgen receptor (AR-FL) expression, response to therapy, and gene expression were determined.RESULTS. We demonstrated that AR-V7 protein is rarely expressed (CONCLUSION. This study provides impetus to develop therapies that abrogate AR-V7 signaling to improve our understanding of AR-V7 biology and to confirm the clinical significance of AR-V7.FUNDING. Work at the University of Washington and in the Plymate and Nelson laboratories is supported by the Department of Defense Prostate Cancer Research Program (W81XWH-14-2-0183, W81XWH-12-PCRP-TIA, W81XWH-15-1-0430, and W81XWH-13-2-0070), the Pacific Northwest Prostate Cancer SPORE (P50CA97186), the Institute for Prostate Cancer Research, the Veterans Affairs Research Program, the NIH/National Cancer Institute (P01CA163227), and the Prostate Cancer Foundation. Work in the de Bono laboratory was supported by funding from the Movember Foundation/Prostate Cancer UK (CEO13-2-002), the US Department of Defense (W81XWH-13-2-0093), the Prostate Cancer Foundation (20131017 and 20131017-1), Stand Up To Cancer (SU2C-AACR-DT0712), Cancer Research UK (CRM108X-A25144), and the UK Department of Health through an Experimental Cancer Medicine Centre grant (ECMC-CRM064X)., IntroductionProstate cancer (PC) is the most commonly diagnosed noncutaneous cancer and the second leading cause of male cancer-related death in the Western world (1). Androgen receptor (AR) signaling is critical [...]

Published
2019
Full Text
View/download PDF

3. Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer

Author

Sharp, Adam, primary, Coleman, Ilsa, additional, Yuan, Wei, additional, Sprenger, Cynthia, additional, Dolling, David, additional, Rodrigues, Daniel Nava, additional, Russo, Joshua W., additional, Figueiredo, Ines, additional, Bertan, Claudia, additional, Seed, George, additional, Riisnaes, Ruth, additional, Uo, Takuma, additional, Neeb, Antje, additional, Welti, Jonathan, additional, Morrissey, Colm, additional, Carreira, Suzanne, additional, Luo, Jun, additional, Nelson, Peter S., additional, Balk, Steven P., additional, True, Lawrence D., additional, de Bono, Johann S., additional, and Plymate, Stephen R., additional

Published
2018
Full Text
View/download PDF

4. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Author

Rodrigues, Daniel Nava, primary, Rescigno, Pasquale, additional, Liu, David, additional, Yuan, Wei, additional, Carreira, Suzanne, additional, Lambros, Maryou B., additional, Seed, George, additional, Mateo, Joaquin, additional, Riisnaes, Ruth, additional, Mullane, Stephanie, additional, Margolis, Claire, additional, Miao, Diana, additional, Miranda, Susana, additional, Dolling, David, additional, Clarke, Matthew, additional, Bertan, Claudia, additional, Crespo, Mateus, additional, Boysen, Gunther, additional, Ferreira, Ana, additional, Sharp, Adam, additional, Figueiredo, Ines, additional, Keliher, Daniel, additional, Aldubayan, Saud, additional, Burke, Kelly P., additional, Sumanasuriya, Semini, additional, Fontes, Mariane Sousa, additional, Bianchini, Diletta, additional, Zafeiriou, Zafeiris, additional, Mendes, Larissa Sena Teixeira, additional, Mouw, Kent, additional, Schweizer, Michael T., additional, Pritchard, Colin C., additional, Salipante, Stephen, additional, Taplin, Mary-Ellen, additional, Beltran, Himisha, additional, Rubin, Mark A., additional, Cieslik, Marcin, additional, Robinson, Dan, additional, Heath, Elizabeth, additional, Schultz, Nikolaus, additional, Armenia, Joshua, additional, Abida, Wassim, additional, Scher, Howard, additional, Lord, Christopher, additional, D’Andrea, Alan, additional, Sawyers, Charles L., additional, Chinnaiyan, Arul M., additional, Alimonti, Andrea, additional, Nelson, Peter S., additional, Drake, Charles G., additional, Van Allen, Eliezer M., additional, and de Bono, Johann S., additional

Published
2018
Full Text
View/download PDF

5. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer

Author

Nava Rodrigues, Daniel, primary, Rescigno, Pasquale, additional, Liu, David, additional, Yuan, Wei, additional, Carreira, Suzanne, additional, Lambros, Maryou B., additional, Seed, George, additional, Mateo, Joaquin, additional, Riisnaes, Ruth, additional, Mullane, Stephanie, additional, Margolis, Claire, additional, Miao, Diana, additional, Miranda, Susana, additional, Dolling, David, additional, Clarke, Matthew, additional, Bertan, Claudia, additional, Crespo, Mateus, additional, Boysen, Gunther, additional, Ferreira, Ana, additional, Sharp, Adam, additional, Figueiredo, Ines, additional, Keliher, Daniel, additional, Aldubayan, Saud, additional, Burke, Kelly P., additional, Sumanasuriya, Semini, additional, Fontes, Mariane Sousa, additional, Bianchini, Diletta, additional, Zafeiriou, Zafeiris, additional, Teixeira Mendes, Larissa Sena, additional, Mouw, Kent, additional, Schweizer, Michael T., additional, Pritchard, Colin C., additional, Salipante, Stephen, additional, Taplin, Mary-Ellen, additional, Beltran, Himisha, additional, Rubin, Mark A., additional, Cieslik, Marcin, additional, Robinson, Dan, additional, Heath, Elizabeth, additional, Schultz, Nikolaus, additional, Armenia, Joshua, additional, Abida, Wassim, additional, Scher, Howard, additional, Lord, Christopher, additional, D’Andrea, Alan, additional, Sawyers, Charles L., additional, Chinnaiyan, Arul M., additional, Alimonti, Andrea, additional, Nelson, Peter S., additional, Drake, Charles G., additional, Van Allen, Eliezer M., additional, and de Bono, Johann S., additional

Published
2018
Full Text
View/download PDF

6. BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity.

Author

Westaby, Daniel, Jiménez-Vacas, Juan M., Figueiredo, Ines, Rekowski, Jan, Pettinger, Claire, Gurel, Bora, Lundberg, Arian, Bogdan, Denisa, Buroni, Lorenzo, Neeb, Antje, Padilha, Ana, Taylor, Joe, Wanting Zeng, Das, Souvik, Hobern, Emily, Riisnaes, Ruth, Crespo, Mateus, Miranda, Susana, Ferreira, Ana, and Hanratty, Brian P.

Subjects
*PROSTATE cancer, *ANDROGEN receptors, *TRANSCRIPTION factors, *CASTRATION-resistant prostate cancer, *NEUROENDOCRINE cells, *EPITHELIAL-mesenchymal transition, *DNA methylation
Abstract

The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of ARindependent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage plasticity, and transformation to prostate cancers (PCs) that exhibit phenotypes of neuroendocrine or basal-like cells. The anti-apoptotic protein BCL2 is upregulated in neuroendocrine cancers and may be a therapeutic target for this aggressive PC disease subset. There is an unmet clinical need, therefore, to clinically characterize BCL2 expression in metastatic CRPC (mCRPC), determine its association with AR expression, uncover its mechanisms of regulation, and evaluate BCL2 as a therapeutic target and/ or biomarker with clinical utility. Here, using multiple PC biopsy cohorts and models, we demonstrate that BCL2 expression is enriched in AR-negative mCRPC, associating with shorter overall survival and resistance to ARSIs. Moreover, high BCL2 expression associates with lineage plasticity features and neuroendocrine marker positivity. We provide evidence that BCL2 expression is regulated by DNA methylation, associated with epithelial-mesenchymal transition, and increased by the neuronal transcription factor ASCL1. Finally, BCL2 inhibition had antitumor activity in some, but not all, BCL2-positive PC models, highlighting the need for combination strategies to enhance tumor cell apoptosis and enrich response. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results